 |
| Scopolamine Market |
Scopolamine is an alkaloid used as pharmaceutical drug primarily prescribed for preventing motion sickness or nausea related to anesthesia and surgery. Scopolamine patches or sublingual tablets are used to treat nausea and vomiting associated with recurring motion sickness especially during travel via ships, boats or planes.
The global
Scopolamine Market is estimated to be valued at US$ 3676.85 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period
2023 to 2030, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The growing adoption of scopolamine patches and sublingual tablets to prevent
motion sickness during frequent travel has been a key factor propelling the
growth of scopolamine market. Rising disposable income and increasing tourism
activities have contributed to rising incidence of motion sickness
necessitating preventive treatment using scopolamine-based pharmaceutical
products. With evolving lifestyle and engagement in regular recreational and
occupational activities involving mode of transport prone to induce motion
sickness, the demand for scopolamine drugs is expected to grow substantially
over the forecast period. Furthermore, ongoing R&D focused on developing
novel drug delivery systems is anticipated to provide new opportunities for
market players in the years to come.
Segment
Analysis
The global scopolamine market is segmented by source, distribution channel,
application, and geography. By source, the bark derived scopolamine sub-segment
currently dominates the market owing to established supply chain and
availability. By distribution channel, the retail pharmacy sub-segment holds
the largest market share due to ease of accessibility and affordability. By
application, the gastrointestinal disorders sub-segment accounts for more than
35% of the market share due to growing prevalence of gastrointestinal issues
worldwide.
Key Takeaways
The global Scopolamine
Market Growth is expected to
witness high growth over the forecast period of 2023 to 2030. The global
Scopolamine Market is estimated to be valued at US$ 3676.85 Bn in 2023 and is
expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
The global scopolamine market is expected to witness high growth over the
forecast period. Regional analysis related content comprises North America
currently dominates the global scopolamine market with over 40% share due to
well-established healthcare infrastructure and rising R&D investments in
drug development.
Key players
related content comprises Key players operating in the scopolamine market are
Baxter International Inc., GlaxoSmithKline plc, Novartis AG, Perrigo Company
plc, Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD.
For more insights, read- https://www.ukwebwire.com/scopolamine-market-trends-size-and-share-analysis-2/
Comments
Post a Comment